Meet the course team
To enhance your learning, we have gathered a group of experts on antibiotic resistance and they’re all working at Uppsala University.
The overall lead for this course is Thomas Tängdén, who you already met in the welcome video. He is an infectious disease physician, researcher and the medical director of the global network ReAct - Action on Antibiotic Resistance. Thomas will return later in the course and give a lecture (Week 2) about bacterial evolution and the importance of the normal flora.
The second lead educator of this course is Saga Alvring who is a public health scientists (BSc, MPH) working at ReAct (although she is currently on maternity leave). She has developed large parts of the course content.
The course features mentoring by Karin Malmros who is an infection biologist working as a postdoc at ReAct. She holds a PhD in molecular bacteriology and infection and has also helped to develop content (e.g., factsheet, quiz, references) of this course.
Thomas and Karin will be available for questions and take part in the discussions throughout the course.
You can follow us by selecting the links to our FutureLearn profile pages and then selecting Follow. That way, you’ll easily be able to see the comments we make in the various steps of the course.
Our first lecturer is Otto Cars, who is senior professor of infectious diseases and the founder of ReAct. He has spent more than 20 years to alert the outside world about the risks of antibiotic resistance and is frequently employed as an expert and advisor by WHO, other institutions and high-level politicians. Otto’s first lecture (Week 1) will be about the current situation and his second lecture (Week 4) about what he thinks are the key tools to tackle antibiotic resistance.
Maria Pränting is a microbiologist and the scientific officer of ReAct. She holds a PhD in medical microbiology and her research has mainly focused on examining development of bacterial resistance to antimicrobial peptides. Maria will give a lecture (Week 2) about emergence and spread of antibiotic-resistant bacteria. She also helped in developing some of the factsheets of this course.
Hanna Montelin is an infectious disease physician and PhD candidate working at Uppsala University Hospital. Hanna will talk (Week 2) about the challenges in clinical practice she faces in her daily work at the hospital.
Diarmaid Hughes is a professor of medical molecular bacteriology and is interested in bacterial genetics and evolution, including the evolution of resistance to antibiotics. He is engaged in the ENABLE project, which is a public-private collaboration aiming to advance the discovery and development of new Gram-negative antibiotics. Diarmaid will give a lecture (Week 3) about the challenges in discovering new antibiotics and the need for innovation in the field.
Francesco Ciabuschi is a professor of international business and is interested in developing new business models addressing antibiotic resistance. He is a leading partner in the DRIVE-AB project, which aims to design new business models that would provide industry with an incentive to develop of new antibiotics while ensuring that they are used wisely. Francesco will give a lecture (Week 3) about the need for new business models addressing antibiotic resistance.
Stefan Swartling Peterson is a professor of global health and a cofounder of the Swedish Doctors Without Borders (MSF). He has spent more than 20 years working on child survival, perinatal quality of care and capacity development in East Africa. Stefan will give a lecture (Week 3) about how antibiotics should be distributed to balance access against the risk of excessive use in low- and middle-income countries. Stefan is currently working as the chief of health at UNICEF in New York.
At the end of the course, the lecturers will share their views in a concluding panel discussion (Week 4). The panel will be moderated by Jessica Lönn-Stensrud, who works as a senior academic librarian at the University of Oslo. She holds a PhD in microbiology and her research research interest lies in antibiotic resistance, biofilms, and infections.
© Uppsala University